FDA clears IND for Ph 1/2a trial (TCX-101) of BSB-1001 for patients with R/R AML, ALL and MDS, in conjunction with alloHSCT June 11, 2024
First Patient Dosed in Investigator-Initiated Trial (IIT) of Danvatirsen in Ph 1 for AML/MDS Cancers May 21, 2024
First Patients Dosed in Two Ph 1 Trials of REM-422 of Adenoid Cystic Carcinoma (ACC) and AML/MDS May 7, 2024
Additional Positive Data announced from Ph 1 Part of BEXMAB Study in Both Higher-Risk HMA-Failed MDS and R/R AML March 26, 2024
First Patient dosed in the RIVER-52 Ph 2 Study of RVU120 for the Treatment of Patients with R/R AML and HR-MDS February 26, 2024
Final Results of Ph 3 ASCERTAIN Trial of Oral Decitabine and Cedazuridine Fixed Dose Combination (INQOVI®) in Patients With MDS and CMML published February 16, 2024
Investigator-initiated Ph 1/2 Trial of Seclidemstat + Azacitidine to Treat Heme Cancers Resumes Patient Enrollment January 10, 2024
Orum Therapeutics Announces Acquisition of ORM-6151 Program by Bristol Myers Squibb December 11, 2023
AbbVie is terminating its agreement with I-Mab to develop certain CD47 antibody compounds, including the programme’s lead drug lemzoparlimab October 3, 2023
FDA Filing Acceptance and Priority Review for TIBSOVO in the Treatment of IDH1-mutated R/R MDS announced August 23, 2023
Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS To Discontinue August 2, 2023
Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs for Genetic Diseases, AML and MDS July 5, 2023
First Patient Dosed in Ph 2 IMpress Trial of Imetelstat in Patients with R/R AML or Higher Risk MDS June 21, 2023
Coeptis Therapeutics to Acquire Allogeneic Immuno-Oncology NK Platform in Ph 1 Trials from Deverra Therapeutics April 27, 2023
Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome February 1, 2023
Positive Top-Line Results from IMerge Ph 3 Trial of Imetelstat in Lower Risk MDS Announced January 11, 2023
